The total number of records retrieved from this search are 40. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_268	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result92% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_269	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result95% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_270	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result92% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_271	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result90% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_272	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result88% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_273	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result92% cancer cell viability at 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_274	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result85% cancer cell viability at 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_275	Virus nameAdenovirus	Virus strainAd.sp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result90% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26554307
IDOV_283	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result88% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_284	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result75% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_285	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result77% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_286	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result74% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_287	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result70% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_288	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result90% cancer cell viability at 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_289	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result83% cancer cell viability at 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_290	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result71% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_298	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result78% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_299	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneNo	Virus in combination with drug/radiationVirus combined with recombinant human CD47 Fc chimera (rhCD47-Fc) - 1μg/mL	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result82% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_300	Virus nameAdenovirus	Virus strainAd.4N1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 expression cassette	Virus aloneNo	Virus in combination with drug/radiationVirus combined with recombinant human CD47 Fc chimera (rhCD47-Fc) - 5μg/mL	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result96% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_305	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result92% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_306	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result65% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_307	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result58% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_308	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration150 MOI	In-vitro result52% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_309	Virus nameAdenovirus	Virus strainAd.4N1-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral E1A promoter was replaced by human survivin promoter (hsurP) and contains a sCAR-4N1 with IL-24 expression cassettes	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineLeukemia cell line	Cell lineK562	Concentration of cell line2.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration200 MOI	In-vitro result44% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduces apoptosis by upregulating Bax and activated caspase 3 levels	Immunogenic effectInduces expression of IL-24	Clinical trialNA	PMID26554307
IDOV_753	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration10 MOI	In-vitro result90% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_754	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result58% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_755	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result41% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_756	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration120 MOI	In-vitro result36% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_757	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration160 MOI	In-vitro result25% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_783	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration10 MOI	In-vitro result90% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_784	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result57% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_785	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result30% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_786	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration120 MOI	In-vitro result11% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_787	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration160 MOI	In-vitro result9% cancer cell viability at 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_813	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with DNR 40 ng/ml	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result50% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_814	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with DNR 120 ng/ml	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration40 MOI	In-vitro result42% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_821	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with DNR 40 ng/ml	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result35% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_822	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with DNR 120 ng/ml	Immune gene insertion in viral genomeNo	Source of cell lineGibco, Thermo Fisher Scientific, Waltham, MA, USA	Origin of cell lineHuman chronic myelogenous leukemic cell line	Cell lineK562	Concentration of cell line1.0E+4 cells per well	In-vitro toxicitySlight toxicity to L-02 and BJ cell line	AssayCell counting kit-8 (CCK-8) assay	In-vitro virus concentration80 MOI	In-vitro result29% cancer cell viability at 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_5635	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman leukemia cell line	Cell lineK562	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5.4 ×10⁴ pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5855	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman leukemia cell line	Cell lineK562	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration5.4 ×10⁴ pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578